Mesenchymal Tumor Of The Gastrointestinal Tract is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Mesenchymal Tumor Of The Gastrointestinal Tract have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Mesenchymal Tumor Of The Gastrointestinal Tract compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesenchymal Tumor Of The Gastrointestinal Tract overview
Mesenchymal tumors represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterized by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely, mesenchymal lesions may occur in the gastrointestinal (GI) tract. Some of these entities occur almost exclusively in the GI tract, whereas other subtypes, when located in the GI tract, may assume distinct morphological features. The majority of sarcomas of the GI tract are represented by gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors in the stomach as well as in the small bowel. GIST represents a distinctive mesenchymal neoplasm sharing immunomorphologic features with the interstitial cell of Cajal. It exhibits an exclusive tropism for the GI tract.
For a complete picture of PTSR and LoA scores for drugs in Mesenchymal Tumor Of The Gastrointestinal Tract, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
